ChromaDex Corporation (CDXC): Price and Financial Metrics


ChromaDex Corporation (CDXC): $1.87

-0.02 (-1.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CDXC to Watchlist
Sign Up

Industry: Chemicals


Ranked

of

in industry

CDXC POWR Grades

  • CDXC scores best on the Growth dimension, with a Growth rank ahead of 82.59% of US stocks.
  • The strongest trend for CDXC is in Growth, which has been heading up over the past 177 days.
  • CDXC's current lowest rank is in the Momentum metric (where it is better than 10.29% of US stocks).

CDXC Stock Summary

  • CDXC has a higher market value than merely 22.15% of US stocks; more precisely, its current market capitalization is $140,745,784.
  • CHROMADEX CORP's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 84.57% of US listed stocks.
  • The ratio of debt to operating expenses for CHROMADEX CORP is higher than it is for about just 12.74% of US stocks.
  • Stocks that are quantitatively similar to CDXC, based on their financial statements, market capitalization, and price volatility, are OTLY, NAOV, HNST, STIM, and EVER.
  • CDXC's SEC filings can be seen here. And to visit CHROMADEX CORP's official web site, go to www.chromadex.com.

CDXC Valuation Summary

  • In comparison to the median Healthcare stock, CDXC's price/earnings ratio is 132.58% lower, now standing at -7.2.
  • Over the past 167 months, CDXC's EV/EBIT ratio has gone down 3.8.

Below are key valuation metrics over time for CDXC.

Stock Date P/S P/B P/E EV/EBIT
CDXC 2023-01-30 2.1 7.0 -7.2 -6.7
CDXC 2023-01-27 2.3 7.5 -7.7 -7.3
CDXC 2023-01-26 2.1 6.9 -7.1 -6.7
CDXC 2023-01-25 2.1 6.7 -6.9 -6.5
CDXC 2023-01-24 2.1 6.7 -6.9 -6.5
CDXC 2023-01-23 2.0 6.4 -6.6 -6.2

CDXC Growth Metrics

    The 5 year net cashflow from operations growth rate now stands at -24724.35%.
  • The year over year cash and equivalents growth rate now stands at -53.03%.
  • The 4 year net cashflow from operations growth rate now stands at -24724.35%.
CDXC's revenue has moved up $22,522,000 over the prior 33 months.

The table below shows CDXC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 68.813 -19.714 -20.447
2022-06-30 69.058 -21.893 -28.318
2022-03-31 70.025 -25.956 -27.487
2021-12-31 67.449 -24.163 -27.128
2021-09-30 65.135 -19.197 -27.9
2021-06-30 62.007 -17.123 -23.259

CDXC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDXC has a Quality Grade of C, ranking ahead of 67.33% of graded US stocks.
  • CDXC's asset turnover comes in at 1.115 -- ranking 18th of 682 Pharmaceutical Products stocks.
  • MYGN, REPH, and ENDP are the stocks whose asset turnover ratios are most correlated with CDXC.

The table below shows CDXC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.115 0.615 -3.082
2021-06-30 1.178 0.612 -2.751
2021-03-31 1.276 0.607 -3.100
2020-12-31 1.545 0.595 -2.616
2020-09-30 1.466 0.586 -2.883
2020-06-30 1.361 0.577 -2.841

CDXC Price Target

For more insight on analysts targets of CDXC, see our CDXC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.80 Average Broker Recommendation 1.3 (Strong Buy)

CDXC Stock Price Chart Interactive Chart >

Price chart for CDXC

CDXC Price/Volume Stats

Current price $1.87 52-week high $3.16
Prev. close $1.89 52-week low $1.15
Day low $1.85 Volume 30,489
Day high $1.93 Avg. volume 245,683
50-day MA $1.77 Dividend yield N/A
200-day MA $1.70 Market Cap 139.26M

ChromaDex Corporation (CDXC) Company Bio


ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. The company is based inIrvine, California.


CDXC Latest News Stream


Event/Time News Detail
Loading, please wait...

CDXC Latest Social Stream


Loading social stream, please wait...

View Full CDXC Social Stream

Latest CDXC News From Around the Web

Below are the latest news stories about CHROMADEX CORP that investors may wish to consider to help them evaluate CDXC as an investment opportunity.

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

LOS ANGELES, January 31, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational Neurodegeneration by a team of scientists led by Dr. Adil Mardinoglu, Professor of Systems Biology in the Science for Life Laboratory at the Royal Institute of Technology (KTH), Stockholm, Sweden ​​and Centre for Host-Microbiome Interaction at the King’s Co

Yahoo | January 31, 2023

ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

LOS ANGELES, January 17, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind five-month-long clinical study, as reported in the peer-reviewed journal Science Advances by a team of scientists led by Dr. Eija Pirinen (University of Helsinki and University of Oulu) and Dr. Kirsi Pietiläinen (University of Helsinki).

Yahoo | January 17, 2023

Strong week for ChromaDex (NASDAQ:CDXC) shareholders doesn't alleviate pain of five-year loss

ChromaDex Corporation ( NASDAQ:CDXC ) shareholders will doubtless be very grateful to see the share price up 51% in the...

Yahoo | January 15, 2023

ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

LOS ANGELES, January 12, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Scientific Advisory Board (SAB). Dr. Bohr is one of the world’s most published researchers on aging and neurodegenerative disease with over 590 journal publications. For the past 30 years, Dr. Bohr served as Chief of the Laboratory of Molecular Genetics at the National Institute on Aging, which is part

Yahoo | January 12, 2023

ChromaDex Named Brianna Gerber Chief Financial Officer

LOS ANGELES, January 05, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023. Gerber served as Senior Vice President, Finance / Interim Chief Financial Officer of ChromaDex since August 11, 2022, and prior to that was the Vice President of Finance and Investor Relations of ChromaDex since September 17, 2018.

Yahoo | January 5, 2023

Read More 'CDXC' Stories Here

CDXC Price Returns

1-mo -2.60%
3-mo 6.25%
6-mo 12.65%
1-year -27.24%
3-year -53.71%
5-year -64.78%
YTD 11.31%
2022 -55.08%
2021 -22.08%
2020 11.37%
2019 25.66%
2018 -41.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7862 seconds.